Safety and Efficacy Of Amber Peripheral Liquid Embolic System

Inclusion Criteria: * Patients aged ≥ 18 and \< 95 years presenting with one of the following indications: * Varicose vein embolization: * Pelvic congestion syndrome (uterine venous engorgement, and/or moderate or severe engorgement of the ovarian plexus, and/or filling of the veins across the midline or filling of vulvar or thigh varicosities, and/or reflux throughout the entire course of the ovarian vein. * Varicocele (symptomatic varicocele, and/or infertility or subfertility). * Varicose veins in patients with portal hypertension undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) that require embolization. * Type II endoleak: Persistent type II endoleak and/or an associated sac expansion \> 5 mm after 6 months or 10 mm after 12 months. * Insufficient liver remnant requiring portal vein embolization (PVE) before liver resection: Predicted insufficient liver remnant after surgery (≤20% in a normal liver, ≤30% in liver with intermediate disease without cirrhosis, and ≤40% in liver with cirrhosis) * Active arterial hemorrhage and/or pseudoaneurysm: Uncontrolled massive hemorrhage caused by tumor, trauma or arteriovenous shunt formation (congenital or acquired), and/or up to 3 bleeding sites in the same organ or anatomic region * Pathologic organ (i.e. non-functioning transplanted kidney, preoperative hip replacement, hypersplenism conditioning low platelet count; excluding brain) * Hypervascular tumors * Vascular anomalies Exclusion Criteria: * Patients with known hypersensitivity or allergy to amber-20, dimethylsulfoxide (DMSO) solvent, or contrast agent * Previously failed embolization procedure, except for those treated with coils * Patient in whom according to the investigator criteria a complete vascular occlusion would not be feasible in a single procedure * Any condition that exposes the patient to a high risk for complications according to the investigator's criteria (e.g., but not limited to, non-correctable coagulopathy, uncontrolled sepsis, underlying life-threatening condition, etc.) * Patients participating in another interventional study that has not completed it primary endpoint assessment. * Pregnant or breastfeeding women. * Patients unable or unwilling to provide a written informed consent. * Recurrent varicose vein embolization * Type II endoleak: with high flow or reflux that cannot be prevented using coils or balloon microcatheter, and high risk of medullar ischemic damage * Active arterial bleeding and/or pseudo aneurysm with: severe hemodynamical instability (e.g., but not limited to, sustained hypotension \[mean arterial pressure \< 60 mmHg\], tachycardia \>120 beats/minute, requirement of high doses of vasopressors, etc.) at the moment of the procedure, and/or hb \< 8 g/dL before the procedure, and/or retroperitoneal hemorrhages or hemoptysis, identification of spinal or medullar vessels. * Central nervous system and central circulatory system vascular anomalies. * Iodine contrast allergy